

Altimmune to Present at Upcoming Investor and Scientific Conferences

February 4, 2020

GAITHERSBURG, Md., Feb. 04, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that management will present at the following conferences during the months of February:

2020 BIO CEO & Investor Conference

Date:	Monday, February 10
Time:	10:45am ET
Title:	Altimmune, Inc. Overview
Speaker:	Vipin K. Garg Ph. D., President and Chief Executive Officer
Location:	New York Marriott Marquis, New York, NY
Webcast:	https://ir.altimmune.com/investors/events-and-presentations

The 3rd Global NASH Conference

Date:	Tuesday, February 11
Time:	11:55 am GMT / 6:55 am ET
Title:	Dual GLP-1 Agonists in the Treatment of Metabolic & Liver Dysfunction in NASH
Speaker:	M. Scott Harris M.D., Chief Medical Officer
Location:	The London Heathrow Marriott Hotel, London, UK
Presentation:	https://ir.altimmune.com/investors/events-and-presentations

About Altimmune

Altimmune is a clinical stage biopharmaceutical company focused on developing treatments for liver diseases and immune modulating therapies. The Company's diverse pipeline includes next generation peptide therapeutics for NASH (ALT-801) and chronic Hepatitis B (HepTcell[™]), conjugated immunostimulants for the treatment of cancer (ALT-702) and intranasal vaccines (NasoShield[™] and NasoVAX[™]). For more information on Altimmune, please visit <u>www.altimmune.com</u>.

Contacts

Will Brown Chief Financial Officer Phone: 240-654-1450 Email: wbrown@altimmune.com

altimmune

Ashley R. Robinson Managing Director LifeSci Advisors Phone: 617-535-7742 Email: arr@lifesciadvisors.com

Source: Altimmune, Inc.